HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

>2 years >20 visits Confirmation phase (III)No Placebo Cost Reimbursement Partially Remote Investigational Medicines InjectionGynecology and ObstetricsOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bevacizumab

Bevacizumab is a substance that blocks formation of new blood vessels to treat certain cancers and eye conditions caused by abnormal vessel growth.

Trastuzumab Deruxtecan

Trastuzumab deruxtecan is a targeted cancer treatment that attacks tumors with high HER2 protein levels.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ds-8201a

Vegzelma

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Medizinische Universitaet Innsbruck

University Clinic for Gynecology and Obstetrics

Innsbruck, Austria

Landeskrankenanstalten-Betriebsgesellschaft Kabeg

Department of Gynecology and Obstetrics

Klagenfurt am Wörthersee, Austria

Klinik Hietzing

Dept. f. Gynecology and Obstetrics

Perchtoldsdorf, Austria

Sponsor: Daiichi Sankyo Europe GmbH

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.